secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123324
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q3 net loss $28.7M; LIFT-AD missed endpoints; exploring strategic alternatives
--------------------------------------------------------------------------------

- Net loss $28.7M ($0.75/sh) vs $33.0M ($0.87/sh) Q3 2023; cash $68.9M down from $147.4M at Dec 2023.
- Fosgonimeton (ATH-1017) LIFT-AD Phase 2/3 missed primary and key secondary endpoints; development paused.
- Exploring strategic alternatives with Cantor Fitzgerald; ATH-1105 Phase 1 healthy volunteers on track for year-end 2024.
- R&D expenses $17.9M vs $27.2M; G&A $7.6M vs $7.8M; legal accrual $4.1M from DOJ investigation.
- Plan to begin dosing ATH-1105 in ALS patients in 2025; preclinical data supports HGF-modulating mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024123324/0000950170-24-123324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024123324/atha-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer